APC delivers compounding briefing on Capitol Hill
APC briefed about four dozen House of Representatives healthcare staffers on the practice of pharmacy compounding — and cleared some of the muddied waters.
APC briefed about four dozen House of Representatives healthcare staffers on the practice of pharmacy compounding — and cleared some of the muddied waters.
We learned this week that several compounding pharmacies have received a cease-and-desist letter from a law firm representing Eli Lilly.
Demonstrate your commitment to your patients and practice at APC’s annual DC fly-in for pharmacy compounders, September 17-18 at Hilton National Mall.
The FDA is proposing a rule that would add categories to both the 503A and 503B demonstrably difficult to compound (DDC) lists — a plan that has a host of issues.
The California Board of Pharmacy has proposed several new regulations for pharmacy compounding, some of which, to put it bluntly (and we did put it bluntly), are not rooted in science or evidence.
Well check this out: A news story about compounded GLP-1s that’s actually accurate, sans all the usual hand-wringing and fear-mongering.
Okay, not quite the cover, but APC has certainly been quoted in that and dozens of other publications over the past several months as the GLP-1 phenomenon has shone a bright light on pharmacy compounding.
Learn what’s at stake and what APC is doing about it — and how you can help … even if you don’t compound GLP-1s.
The FDA held a listening session on the "Use and Processes of Advisory Committees" on Thursday. APC's Tenille Davis and PCCA's AJ Day were there.